Pasar al contenido principal

PROYECTO EPIGENESIS. ESTUDIO EPIGENETICO Y GENETICO DE LA EVOLUCION NEUROLOGICA POST ICTUS.

PI17/02089

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION MUTUA DE TERRASSA
Centro realización HOSPITAL MUTUA DE TERRASSA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ICA1L Is Associated with Small Vessel Disease, A Proteome-Wide Association Study in Small Vessel Stroke and Intracerebral Haemorrhage

  • Cullell, Natalia|||0000-0001-5118-1014
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Molina, Jessica
  • Casas, Laura
  • Almeria, Marta|||0000-0001-7445-6113
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Small vessel strokes (SVS) and intracerebral haemorrhages (ICH) are acute outcomes of cerebral small vessel disease (SVD). Genetic studies combining both phenotypes have identified three loci associated with both traits. However, the genetic cis-regulation at the protein level associated with SVD has not been studied before. We performed a proteome-wide association study (PWAS) using FUSION to integrate a genome-wide association study (GWAS) and brain proteomic data to discover the common mechanisms regulating both SVS and ICH. Dorsolateral prefrontal cortex (dPFC) brain proteomes from the ROS/MAP study (N = 376 subjects and 1443 proteins) and the summary statistics for the SVS GWAS from the MEGASTROKE study (N = 237,511) and multi-trait analysis of GWAS (MTAG)-ICH-SVS from Chung et al. (N = 240,269) were selected. We performed PWAS and then a co-localization analysis with COLOC. The significant and nominal results were validated using a replication dPFC proteome (N = 152). The replicated results (q -value < 0.05) were further investigated for the causality relationship using summary data-based Mendelian randomization (SMR). One protein (ICA1L) was significantly associated with SVS (z-score = -4.42 and p -value = 9.6 × 10 -6) and non-lobar ICH (z-score = -4.8 and p -value = 1.58 × 10 -6) in the discovery PWAS, with a high co-localization posterior probability of 4. In the validation PWAS, ICA1L remained significantly associated with both traits. The SMR results for ICA1L indicated a causal association of protein expression levels in the brain with SVS (p -value = 3.66 × 10 -5) and non-lobar ICH (p -value = 1.81 × 10 -5). Our results show that the association of ICA1L with SVS and non-lobar ICH is conditioned by the cis-regulation of its protein levels in the brain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sleep/wake cycle alterations as a cause of neurodegenerative diseases, A Mendelian randomization study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Amaut, K.E.U.
  • Krupinski, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Sleep and/or wake cycle alterations are common in neurodegenerative diseases (ND). Our aim was to determine whether there is a causal relationship between sleep and/or wake cycle patterns and ND (Parkinson's disease (PD) age at onset (AAO), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS)) using two-sample Mendelian Randomization (MR). We selected 12 sleep traits with available Genome-Wide Association Study (GWAS) to evaluate their causal relationship with the ND risk through Inverse-Variance Weighted regression as main analysis. We used as outcome the latest ND GWAS with available summary-statistics: PD-AAO (N = 17,996), AD (N = 21,235) and ALS (N = 40,136). MR results pointed to a causal effect of subjective and objective-measured morning chronotype on later PD-AAO (95%CI:0.33-1.81, p = 8.47×10 and 95%CI:-7.28 to -4.44, p = 5.87×10, respectively). Sleep efficiency was causally associated with a decreased AD risk (95%CI:-20.408 to -0.66, p = 0.04) and daytime sleepiness with an increased ALS risk (95%CI:0.15 to 1.61, p = 0.01). Our study suggests that sleep and/or wake patterns have causal relationship with ND. Given that sleep and/or wake patterns are modifiable risk factors, sleep interventions should be investigated as a potential treatment in PD-AAO, AD and ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype

  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Castillo, José
  • Freijo, Marimar
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Obach, Víctor|||0000-0002-0518-1053
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Molina, Carlos A.|||0000-0001-6058-6259
  • Ribo, Marc|||0000-0001-9242-043X
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Diaz-Navarro, Rosa
  • Vives-Bauza, Cristòfol
  • Serrano-Heras, Gemma|||0000-0001-9368-4832
  • Segura, Tomás|||0000-0003-3625-0987
  • Ibañez, Laura
  • Heitsch, Laura
  • Delgado, Pilar
  • Dhar, Rajat|||0000-0002-5167-5097
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Blay, Natalia|||0000-0002-7160-8529
  • Sumoy, Lauro|||0000-0003-0005-4618
  • de Cid, Rafael|||0000-0003-3579-6777
  • Montaner, Joan|||0000-0003-4845-2279
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lee, Jim-Moo
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background: Occult atrial fibrillation (AF) is one of the major causes of embolic stroke of undetermined source (ESUS). Knowing the underlying etiology of an ESUS will reduce stroke recurrence and/or unnecessary use of anticoagulants. Understanding cardioembolic strokes (CES), whose main cause is AF, will provide tools to select patients who would benefit from anticoagulants among those with ESUS or AF. We aimed to discover novel loci associated with CES and create a polygenetic risk score (PRS) for a more efficient CES risk stratification. Methods: Multitrait analysis of GWAS (MTAG) was performed with MEGASTROKE-CES cohort (n = 362,661) and AF cohort (n = 1,030,836). We considered significant variants and replicated those variants with MTAG p-value < 5 × 10 influencing both traits (GWAS-pairwise) with a p-value < 0.05 in the original GWAS and in an independent cohort (n = 9,105). The PRS was created with PRSice-2 and evaluated in the independent cohort. Results: We found and replicated eleven loci associated with CES. Eight were novel loci. Seven of them had been previously associated with AF, namely, CAV1, ESR2, GORAB, IGF1R, NEURL1, WIPF1, and ZEB2. KIAA1755 locus had never been associated with CES/AF, leading its index variant to a missense change (R1045W). The PRS generated has been significantly associated with CES improving discrimination and patient reclassification of a model with age, sex, and hypertension. Conclusion: The loci found significantly associated with CES in the MTAG, together with the creation of a PRS that improves the predictive clinical models of CES, might help guide future clinical trials of anticoagulant therapy in patients with ESUS or AF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered methylation pattern in EXOC4 is associated with stroke outcome, an epigenome-wide association study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Soriano Tárraga, Carolina|||0000-0002-5635-273X
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Esteller, M.|||0000-0003-4490-6093
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Montaner, Joan|||0000-0003-4845-2279
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background and purpose: The neurological course after stroke is highly variable and is determined by demographic, clinical and genetic factors. However, other heritable factors such as epigenetic DNA methylation could play a role in neurological changes after stroke. Methods: We performed a three-stage epigenome-wide association study to evaluate DNA methylation associated with the difference between the National Institutes of Health Stroke Scale (NIHSS) at baseline and at discharge (ΔNIHSS) in ischaemic stroke patients. DNA methylation data in the Discovery (n = 643) and Replication (n = 62) Cohorts were interrogated with the 450 K and EPIC BeadChip. Nominal CpG sites from the Discovery (p value < 10) were also evaluated in a meta-analysis of the Discovery and Replication cohorts, using a random-fixed effect model. Metabolic pathway enrichment was calculated with methylGSA. We integrated the methylation data with 1305 plasma protein expression levels measured by SOMAscan in 46 subjects and measured RNA expression with RT-PCR in a subgroup of 13 subjects. Specific cell-type methylation was assessed using EpiDISH. Results: The meta-analysis revealed an epigenome-wide significant association in EXOC4 (p value = 8.4 × 10) and in MERTK (p value = 1.56 × 10). Only the methylation in EXOC4 was also associated in the Discovery and in the Replication Cohorts (p value = 1.14 × 10 and p value = 1.3 × 10, respectively). EXOC4 methylation negatively correlated with the long-term outcome (coefficient = - 4.91) and showed a tendency towards a decrease in EXOC4 expression (rho = - 0.469, p value = 0.091). Pathway enrichment from the meta-analysis revealed significant associations related to the endocytosis and deubiquitination processes. Seventy-nine plasma proteins were differentially expressed in association with EXOC4 methylation. Pathway analysis of these proteins showed an enrichment in natural killer (NK) cell activation. The cell-type methylation analysis in blood also revealed a differential methylation in NK cells. Conclusions: DNA methylation of EXOC4 is associated with a worse neurological course after stroke. The results indicate a potential modulation of pathways involving endocytosis and NK cells regulation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of COVID-19 infection on cognition and its association with neurological symptoms

  • Almeria, Marta|||0000-0001-7445-6113
  • Cejudo, Juan Carlos|||0000-0001-6355-8499
  • Sanz-Santos, José|||0000-0001-8354-414X
  • Deus Yela, Juan|||0000-0002-3305-2662
  • Krupinski, Jerzy|||0000-0002-5136-8898
Objective: To characterize the cognitive profile following COVID-19 infection and its possible association to clinical symptoms, emotional disturbance, biomarkers, and disease severity. Methods: This was a single-center cross-sectional cohort study. Subjects between 20- and 60-year old with confirmed COVID-19 infection were included. Evaluation was performed between April 2020 and July 2021. Patients with previous cognitive impairment and other neurological or severe psychiatric disorders were excluded. Demographic and laboratory data were extracted from the medical records. Results: Altogether 200 patients were included, 85 subjects were female (42.3%), and mean age was 49.12 years (SD: 7.84). Patients were classified into four groups: nonhospitalized (NH, n = 21), hospitalized without intensive care unit (ICU) nor oxygen therapy (HOSP, n = 42), hospitalized without ICU but with oxygen therapy (OXY, n = 107), and ICU (ICU, n = 31) patients. NH group was younger (p =.026). No significant differences were found in any test performed attending severity of illness (p >.05). A total of 55 patients reported subjective cognitive complaints (SCC). Subjects with neurological symptoms (NS) performed worse in trail making test B (p =.013), digits backwards (p =.006), letter&numbers (p =.002), symbol digit modalities test (p =.016), and Stroop color (p =.010) tests. Conclusions: OXY patients and females referred more SCC associated with symptoms of anxiety and depression. Objective cognitive performance was unrelated to SCC. No cognitive impairment was found regarding the severity of COVID-19 infection. Results suggest that NS such as headache, anosmia, and dysgeusia during infection were a risk factor for later cognitive deficits. Tests assessing attention, processing speed, and executive function were the most sensitive in detecting cognitive changes in these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long Neurocognitive and Neuropsychiatric Sequelae in Participants with Post-COVID-19 Infection, A Longitudinal Study

  • Almeria, Marta|||0000-0001-7445-6113
  • Cejudo, Juan Carlos|||0000-0001-6355-8499
  • Deus Yela, Juan|||0000-0002-3305-2662
  • Krupinski, Jerzy|||0000-0002-5136-8898
Objective: To evaluate and characterize the cognitive changes in COVID-19 participants at 6-month follow-up, and to explore a possible association with clinical symptoms, emotional disturbance and disease severity. Methods: This single-center longitudinal cohort study included participants aged 20 and 60 years old to exclude cognitive impairment age-associated with confirmed COVID-19 infection. The initial evaluation occurred 10 to 30 days after hospital or ambulatory discharge, with a subsequent follow-up at 6 months. Patients who had a history of cognitive impairment, neurological conditions, or serious psychiatric disorders were not included. Information on demographics and laboratory results was gathered from medical records. Cognitive outcomes were assessed with a neuropsychological battery including attention, verbal and visual memory, language and executive function tests. Results: A total of 200 participants were included in the study, and 108 completed the follow-up visit. At the 6-month follow-up, comparing the means from baseline with those of the follow-up evaluation, significant overall improvement was observed in verbal and visual memory subtests (p = 0.001), processing speed (p = 0.001), executive function (p = 0.028; p = 0.016) and naming (p = 0.001), independently of disease severity and cognitive complaints. Anxiety and depression were significantly higher in groups with Subjective Cognitive Complaints (SCC) compared to those without (p < 0.01 for both). Conclusions: Persistent symptoms are common regardless of disease severity and are often linked to cognitive complaints. Six months after COVID-19, the most frequently reported symptoms included headache, dyspnea, fatigue, cognitive complaints, anxiety, and depression. No cognitive impairment was found to be associated with the severity of COVID-19. Overall, neuropsychological and psychopathological improvement was observed at 6 months regardless of disease severity and cognitive complaints.